Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
AbstractThe current COVID-19 pandemic influences many aspects of personal and social in-teraction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
(ARIA-EAACI consensus document, Allergy. 2020;75(7):1546-1554)